Home › Research › Mild cognitive impairment
LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease
Quanjun Zhang, Lan-ke Yu, Xin-yuan Zhang, You Wu, Heng Zhang, Jia-lin Wu, Zhaohui Yao, for the Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer s Disease, 2025-06-27
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease (AD) is a neurodegenerative disorder with complex pathological features and pathogenesis, involving aspects such as amyloid-β (Aβ) deposition and neuroinflammation. AD lacks the specific biomarkers for diagnosis, which restricts diagnosis. Recent studies have indicated that Lipocalin-2 (LCN2) plays a direct or indirect role in the occurrence and development of AD. However, whether LCN2 can serve as a biomarker for AD diagnosis remains unclear. Objective This study aims to investigate the role of LCN2 in AD and its potential as a biomarker for diagnosis from a clinical perspective. Methods We analyze the participant demographic information, LCN2 and Aβ 42 levels in cerebrospinal fluid (CSF), and cortex thickness from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database with Welch ANOVA, Linear regression models and other statistical methods. Results LCN2 levels in the CSF of AD patients were significantly higher than those in individuals with mild cognitive impairment and no cognitive impairment. The LCN2 levels were closely associated with cognitive decline and pathological features of AD, including Aβ deposition, and reduced cortical thickness, but no tau protein phosphorylation. Age was an important confounding factor affecting the relationship between LCN2 and Aβ 42 , while gender, years of education, and APOE carrier status did not have a significant impact. Furthermore, LCN2 was linked to the upregulation of inflammatory markers, indicating its potential involvement in the neuroinflammatory processes of AD. Conclusions LCN2 is not only a potential biomarker for the early diagnosis of AD but may also play a significant role in the neurodegenerative processes associated with the disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, Q., Yu, L.-k., Zhang, X.-y., Wu, Y., Zhang, H., Wu, J.-l., et al. (2025). LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251352411
Vancouver
Zhang Q, Yu L.-k, Zhang X.-y, Wu Y, Zhang H, Wu J.-l, et al. LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251352411. PMID: 40576449.
BibTeX
@article{zhang2025-40576449,
author = {Zhang, Quanjun and Yu, Lan-ke and Zhang, Xin-yuan and Wu, You and Zhang, Heng and Wu, Jia-lin and Yao, Zhaohui and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease}},
journal = {Journal of Alzheimer s Disease},
year = {2025},
doi = {10.1177/13872877251352411},
pmid = {40576449},
url = {https://doi.org/10.1177/13872877251352411}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Recent studies have indicated that Lipocalin-2 (LCN2) plays a direct or indirect role in the occurrence and development of AD.
- Results LCN2 levels in the CSF of AD patients were significantly higher than those in individuals with mild cognitive impairment and no cognitive impairment.
- The LCN2 levels were closely associated with cognitive decline and pathological features of AD, including Aβ deposition, and reduced cortical thickness, but no tau protein phosphorylation.
- Age was an important confounding factor affecting the relationship between LCN2 and Aβ 42 , while gender, years of education, and APOE carrier status did not have a significant impact.
- Conclusions LCN2 is not only a potential biomarker for the early diagnosis of AD but may also play a significant role in the neurodegenerative processes associated with the disease.
Why it matters
This study found that cerebrospinal fluid LCN2 levels were significantly higher in Alzheimer's disease patients than in those with mild cognitive impairment or no cognitive impairment, and were associated with cognitive decline, Aβ deposition, and reduced cortical thickness but not tau phosphorylation. It does not test a treatment or cure, but it suggests LCN2 may be a potential diagnostic and progression biomarker.
Study details
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 33 of the 96 points we could judge it on, which is 34 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Renmin Hospital of Wuhan University: institution h-index 427 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40576449) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 33 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 33 of the 96 points we could judge it on is 34 out of 100. |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Mild cognitive impairment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.